{"entity":{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","aka":["Hôtel-Dieu de Nantes","CHU Nantes","University Hospital Hôtel-Dieu"],"tldr":"The university hospital of Nantes, whose haematology department under Philippe Moreau is one of the two French centres that lead the Intergroupe Francophone du Myélome trials.","summary":"The CHU de Nantes is the university hospital of Nantes in western France; its Hôtel-Dieu site houses the Department of Hematology, led by Philippe Moreau. With Lille, Nantes anchors the Intergroupe Francophone du Myélome, and Moreau was first author of the IKEMA and MAIA-era trials and of the 2022 New England Journal of Medicine report of teclistamab in relapsed myeloma. The Institut de Cancérologie de l'Ouest, the region's dedicated cancer centre, is a separate institution.","asOf":"2026-09-18","links":[{"label":"CHU de Nantes","url":"https://www.chu-nantes.fr"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-angers-nantes"],"pathways":[],"terms":[],"trials":[],"people":["philippe-moreau"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nantes","country":"FR","lat":47.212,"lng":-1.553,"institutionType":"hospital","website":"https://www.chu-nantes.fr","university":"Nantes Université","programs":["Multiple myeloma (IFM)","Haematology","Bispecific antibody trials"]},"route":"/institutions/chu-nantes/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"institution":[{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/"}],"person":[{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/"}]}}